daidzin has been researched along with bortezomib in 2 studies
| Studies (daidzin) | Trials (daidzin) | Recent Studies (post-2010) (daidzin) | Studies (bortezomib) | Trials (bortezomib) | Recent Studies (post-2010) (bortezomib) |
|---|---|---|---|---|---|
| 226 | 6 | 105 | 6,868 | 860 | 4,753 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| Ahn, KS; Alahmadi, TA; Alharbi, SA; Chinnathambi, A; Jung, SH; Sethi, G; Yang, MH | 1 |
2 other study(ies) available for daidzin and bortezomib
| Article | Year |
|---|---|
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
Attenuation of STAT3 Signaling Cascade by Daidzin Can Enhance the Apoptotic Potential of Bortezomib against Multiple Myeloma.
Topics: Antineoplastic Agents; Apoptosis; Bortezomib; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Synergism; Humans; Isoflavones; Multiple Myeloma; Phosphorylation; Signal Transduction; STAT3 Transcription Factor | 2019 |